Abivax S.a. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Abivax S.a. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds184 adding, 139 cuttingOf 59 active managers that changed their stake, 32 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 8.9% while net income fell 99.3%: a 90pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Abivax S.a.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 10.3% in a year.
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$1.69 against an average estimate of -$0.86: missed by 97.0%
- Next report
- September 21, 2026
Price chart
- 1 day-1.9%
- 1 week-1.8%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-5.47
Growth
- Share count change
- +10.3%
Cash
- Free cash flow (TTM)
- -$182M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for ABVX from the sources we follow. See filings →
Valuation models
We value Abivax S.a. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Abivax S.a. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Abivax S.a.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.86 | −$1.69 | −97.0% |
| Mar 2026 | −$0.81 | −$0.71 | +12.8% |
| Dec 2025 | −$1.04 | −$1.18 | −13.1% |
| Sept 2025 | −$0.79 | −$2.47 | −214.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 8.4% of tradable shares
- Days to cover
- 5.08 at average volume
- Short interest, 1 month
- +6% to October 15, 2026
- Held by institutions
- 72% of shares
- Held by insiders
- 0.0% of shares
- Employees
- 98 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $647m of assets due within a year against $74m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$278m against $9m of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +10.3%
- year over year
Who owns it
Funds buying and selling- Reported value
- $7.2B
- Institutions reporting
- 301
- Shares held vs prior quarter
- ▲ 9.3%
- Positions opened / closed
- 86 / 39
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Tcg Crossover Management, LLC | $801M | 6.0M | 11.1% | ▼ 7.3% |
| Helikon Investments Ltd | $371M | 2.8M | 5.2% | ▲ 175.0% |
| Darwin Global Management, Ltd. | $348M | 3.6M | 4.8% | ▲ 4.4% |
| Vestal Point Capital, LP | $313M | 2.3M | 4.3% | ▲ 56.6% |
| Jupiter Topco LLC | $255M | 1.9M | 3.5% | — |
| UBS Group AG | $246M | 1.8M | 3.4% | ▼ 59.4% |
| ADAR1 Capital Management, LLC | $240M | 1.8M | 3.3% | ▲ 29.5% |
| Caligan Partners LP | $208M | 1.6M | 2.9% | ▲ 6.6% |
| Citadel Advisors LLC | $192M | 1.4M | 2.7% | ▲ 164.2% |
| Morgan Stanley | $191M | 1.4M | 2.7% | ▼ 16.0% |
| Westfield Capital Management Co LP | $175M | 1.3M | 2.4% | ▼ 1.0% |
| RA Capital Management, L.P. | $151M | 1.1M | 2.1% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Abivax S.a.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Abivax S.a. in brief
- What does Abivax S.a. do?
- Abivax S.a. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Abivax S.a.'s stock ticker?
- Abivax S.a. trades under the ticker ABVX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Abivax S.a.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Tcg Crossover Management, LLC, Helikon Investments Ltd and Darwin Global Management, Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Abivax S.a.
New research on the companies we cover arrives in the weekly email. Free, one email a week.